<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="become indispensable in viral diagnostics. Current applications include: (1) The" exact="detection" post="of (unknown) viral infections in clinical samples. (2) Quantitative"/>
 <result pre="and sample transport, as well as accurate DNA or RNA" exact="isolation" post="are a prerequisite for reliable test results in molecular"/>
 <result pre="for the amplification of viral DNA or RNA for the" exact="detection" post="of viral infections and viral load monitoring. Many virus"/>
 <result pre="applying molecular diagnostics. More complicated diagnostics for genotyping or the" exact="detection" post="of mutations related to therapy failure often rely on"/>
 <result pre="quality control and standardization are important issues! Keywords Diagnosis Virus" exact="detection" post="Variation Genotypes Resistance Introduction In the past, viral culturing"/>
 <result pre="In the past, viral culturing techniques were used for the" exact="detection" post="of viruses in clinical samples. Most of these culture"/>
 <result pre="Most of these culture methods have been replaced by molecular" exact="detection" post="of viruses. The advantages of molecular detection, when compared"/>
 <result pre="and the much shorter time-to-result. A limitation of the molecular" exact="detection" post="of viruses, when compared to conventional culture, is that"/>
 <result pre="for persisting viruses is usually performed by serological methods. The" exact="detection" post="of antibodies is, however, an indirect method to detect"/>
 <result pre="of antibodies is, however, an indirect method to detect an" exact="infection" post="and there is usually no correlation with the severity"/>
 <result pre="and specific resistance-associated mutations. In this chapter applications of molecular" exact="detection" post="of viral infection, viral load monitoring and more complex"/>
 <result pre="and often also less standardized methods, like genotyping and resistance" exact="testing" post="in clinical diagnostics, are discussed. Isolation of Viral Nucleic"/>
 <result pre="is essential. This applies for instance to HIV viral load" exact="testing" post="in plasma. Buffers have been developed for some sample"/>
 <result pre="viral DNA or RNA e.g. by sonication, freezing, special DNA" exact="isolation" post="kits for tissue, etc. Extraction of viral nucleic acids"/>
 <result pre="Viral Detection Methods Several molecular techniques are used for the" exact="detection" post="of viruses. Widely used are target-amplification methods based on"/>
 <result pre="(virology) laboratory is that the laboratory can develop its own" exact="tests" post="for targets for which no CE-marked in vitro diagnostic"/>
 <result pre="available. qPCR can be used for the qualitative and quantitative" exact="detection" post="of viruses. (Multiplex) qPCR can be used for the"/>
 <result pre="detection of viruses. (Multiplex) qPCR can be used for the" exact="detection" post="of many different viruses in one assay, for example"/>
 <result pre="many different viruses in one assay, for example for the" exact="detection" post="of respiratory viruses like influenza virus, para-influenza virus, rhinovirus,"/>
 <result pre="in samples from patients with respiratory disease or for the" exact="detection" post="of norovirus, rotavirus, enteroviruses and parechovirus (gastrointestinal viral panel)"/>
 <result pre="sequence for the design of primers and probes for the" exact="detection" post="of viruses must be unique to the target. Preferably,"/>
 <result pre="3). In the development of primers and probes for the" exact="detection" post="of viruses, however, the variation of the viral genome"/>
 <result pre="the primers and probes and the amplification efficiency. For the" exact="detection" post="of viruses, primers and probes are preferably designed to"/>
 <result pre="reactions, these factors must be taken into account and comprehensive" exact="testing" post="is mandatory when used for patient diagnostics (see Vol."/>
 <result pre="probes that are frequently used in qPCR assays for the" exact="diagnosis" post="of viral infections (Vol. 1, Chap. 3). When these"/>
 <result pre="Applications where mismatch-tolerance is needed are for instance qPCR for" exact="detection" post="of variable viral targets. However, in virology, there are"/>
 <result pre="important that molecular variation is detected, for instance in the" exact="detection" post="of viral variants with different pathogenicity or in the"/>
 <result pre="detection of viral variants with different pathogenicity or in the" exact="detection" post="of mutations that are associated with resistance to antiviral"/>
 <result pre="will be released, thereby releasing the signal. This method allows" exact="detection" post="of the signal at much lower temperatures (until 37"/>
 <result pre="with different characteristics and different pathogenicity, in need of other" exact="treatment" post="strategies. An example is the group of enteroviruses. The"/>
 <result pre="is essential for clinical diagnostics. Another application is the molecular" exact="detection" post="of resistance to antiviral medication. This field is becoming"/>
 <result pre="for several purposes, like genotyping (detection of variation) and the" exact="detection" post="of mutations associated with resistance. A disadvantage is, however,"/>
 <result pre="of only a few mutations is necessary for subtyping or" exact="detection" post="of antiviral resistance. For some applications, for instance genotyping"/>
 <result pre="papillomavirus (HPV), hepatitis B and hepatitis C, or for the" exact="detection" post="of drug-resistant variants for hepatitis B, hybridization assays have"/>
 <result pre="detected. Next generation sequencing methods are more sensitive for the" exact="detection" post="of minor viral populations. LiPA-assays also tend to be"/>
 <result pre="viral populations. LiPA-assays also tend to be better in the" exact="detection" post="of minority strains when compared to Sanger-sequencing methods. Clinical"/>
 <result pre="applying these panels is that all major causes of the" exact="infection" post="are included and can be tested in a single"/>
 <result pre="in a single assay. A disadvantage can be that the" exact="infection" post="of a specific patient is not included in the"/>
 <result pre="infections like hepatitis B, hepatitis C and HIV. Since virus" exact="detection" post="and viral monitoring have become essential in patient care,"/>
 <result pre="laboratories. Automation of the workflow from nucleic acid isolation, amplification," exact="detection" post="and processing of the results is essential for laboratories"/>
 <result pre="results are reproducible. There are three major reasons for quantitative" exact="detection" post="of viral DNA or RNA. The first reason is"/>
 <result pre="In that case, it is also recommended to start antiviral" exact="treatment" post="in the last trimester of the pregnancy. Alternatively, in"/>
 <result pre="for incidents in which health care workers accidently come into" exact="contact" post="with patient fluids that may be contaminated with hepatitis"/>
 <result pre="contaminated with hepatitis B, hepatitis C or HIV. Accidental blood" exact="contact" post="occurs frequently in hospitals. Measures taken after accidental contact"/>
 <result pre="blood contact occurs frequently in hospitals. Measures taken after accidental" exact="contact" post="comprise monitoring of viral load in both the victim"/>
 <result pre="the effect of antiviral treatment. The ultimate goal of antiviral" exact="treatment" post="is to prevent damage to the host by the"/>
 <result pre="to prevent damage to the host by the infection. Antiviral" exact="treatment" post="is installed to reduce the viral load and to"/>
 <result pre="prevent this damage. Applications to monitor the effect of antiviral" exact="treatment" post="are being used for HIV, hepatitis B, hepatitis C"/>
 <result pre="directly after starting therapy can have a predictive value for" exact="treatment" post="success. For some viruses, the absence of a certain"/>
 <result pre="influence the choice of therapy. Viral resistance can occur during" exact="treatment" post="and determines the course of the infection and the"/>
 <result pre="can occur during treatment and determines the course of the" exact="infection" post="and the choice of medication. Often, only small variations,"/>
 <result pre="few examples are discussed in the following subsections. HIV-1 Antiviral" exact="treatment" post="for HIV consists of a combination of antiviral drugs:"/>
 <result pre="co-receptor antagonist (maraviroc) Pharmacokinetic booster agents like ritonavir. Genotypic resistance" exact="testing" post="is usually performed on the reverse transcriptase and protease"/>
 <result pre="reduced susceptibility to integrase inhibitors have been described. Pre-treatment resistance" exact="testing" post="is advised, due to the risk of transmission of"/>
 <result pre="genotypes have only been shown to have minor consequences for" exact="treatment" post="strategies, but they are of interest for predictions. For"/>
 <result pre="genotypes A and B seem to respond relatively well to" exact="treatment" post="with Interferon-alpha, compared to, for instance, genotype C and"/>
 <result pre="Direct-acting antivirals (DAA’s, nucleotide-or nucleoside-analogues) that are available for the" exact="treatment" post="of an infection with the hepatitis B virus are"/>
 <result pre="nucleotide-or nucleoside-analogues) that are available for the treatment of an" exact="infection" post="with the hepatitis B virus are lamivudine, adefovir, telbivudine,"/>
 <result pre="secretion of the HBsAg. Lamivudine has long been the only" exact="treatment" post="option for hepatitis B, but now has been replaced"/>
 <result pre="carry the YMDD variant of hepatitis B. Genotyping and resistance" exact="testing" post="of hepatitis B can be performed by sequencing and"/>
 <result pre="assays have also been developed for genotyping and for the" exact="detection" post="of mutations associated with resistance. Hepatitis C As an"/>
 <result pre="treatment, which aims at long-term suppression of the virus, the" exact="treatment" post="of the hepatitis C virus aims to totally clear"/>
 <result pre="Hepatitis C virus has 7 major genotypes, all with different" exact="prevalence" post="and different responses to treatment. Genotypes 1, 2, 3"/>
 <result pre="not registered for other genotypes. New NS3-protease-inhibitors are registered for" exact="treatment" post="of genotype 1 and 4. Polymerase inhibitors and NS5A"/>
 <result pre="Polymerase inhibitors and NS5A inhibitors show less genotypic specificity. Since" exact="treatment" post="with one antiviral is often ineffective, combination therapy is"/>
 <result pre="resistance does not appear to be a serious problem in" exact="treatment" post="with NS5B polymerase-inhibitors. For NS5A-inhibitors, some clinically relevant mutations"/>
 <result pre="to resistance. Mutations associated with resistance may be present before" exact="treatment" post="or develop during treatment. Pretreatment sequence analysis and monitoring"/>
 <result pre="treatment. Pretreatment sequence analysis and monitoring of response to antiviral" exact="treatment" post="will give more information that may be of help"/>
 <result pre="For HSV 1 and 2, 7–14% of patients that receive" exact="treatment" post="with acyclovir, or similar medications like valaciclovir and famciclovir,"/>
 <result pre="involved in resistance of VZV to antiviral therapy. The first" exact="infection" post="with varicella zoster virus gives chickenpox. Varicella zoster virus"/>
 <result pre="to herpes simplex virus treatment, with acyclovir or foscarnet. Resistance" exact="testing" post="is also performed by sequencing (part of) the thymidine"/>
 <result pre="polymerase genes and comparing to reference sequences. First choice of" exact="treatment" post="for CMV is ganciclovir. Ganciclovir is a guanosine analogue"/>
 <result pre="Compared to influenza A, influenza B is genetically less divers," exact="infection" post="is nearly only restricted to humans and influenza B"/>
 <result pre="inhibitors. Occasionally, resistant strains are found, sometimes related to long-term" exact="treatment" post="of influenza infection in immunocompromised patients. Resistance to oseltamivir"/>
 <result pre="strains are found, sometimes related to long-term treatment of influenza" exact="infection" post="in immunocompromised patients. Resistance to oseltamivir has also been"/>
 <result pre="to zanamivir. Conclusions Molecular diagnostics have become indispensable in the" exact="diagnosis" post="of viral infections. qPCR techniques are not only used"/>
 <result pre="viral infections. qPCR techniques are not only used for the" exact="detection" post="of viruses, but also for viral load determination. Whereas"/>
 <result pre="reveals the dynamic nature of viral genome evolutionNature20054371162116610.1038/nature0423916208317 MacKayaWGet al.Molecular" exact="detection" post="and typing of influenza viruses: are we ready for"/>
 <result pre="HIV-1 genotypic drug resistance informationAntiviral Res2006712–333534210.1016/j.antiviral.2006.05.00316782210 WHO information for molecular" exact="diagnosis" post="of influenza virus—update May 2015. Available at: http://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis_influenza_virus_humans_update_201403rev201505.pdf?ua=1. Accessed"/>
</results>
